The total return over the past 12 months is -89.38% vs. +16.94% for the S&P 500. So far it's up -90.89% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (89.38%) | (67.56%) | (62.18%) | (41.85%) | N/A | N/A |
| Total Return CAGR | (89.38%) | (67.56%) | (62.18%) | (41.85%) | N/A | N/A |
| Revenue CAGR | +6.81% | +0.14% | +7.47% | +97.93% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Karyopharm Therapeutics Inc. (KPTI)
| Year | Start price | End price | KPTI Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $7.36 | $0.67 | (90.89%) | +14.51% | (105.40%) |
| 2025 | $10.14 | $7.36 | (27.42%) | +17.72% | (45.14%) |
| 2024 | $12.98 | $10.14 | (21.88%) | +24.89% | (46.77%) |
| 2023 | $51.00 | $12.98 | (74.55%) | +26.19% | (100.74%) |
| 2022 | $96.30 | $51.00 | (47.04%) | (18.17%) | (28.87%) |
| 2021 | $231.90 | $96.30 | (58.47%) | +28.74% | (87.21%) |
| 2020 | $287.25 | $231.90 | (19.27%) | +18.37% | (37.64%) |
| 2019 | $140.40 | $287.25 | +104.59% | +31.22% | +73.37% |
| 2018 | $143.85 | $140.40 | (2.40%) | (4.56%) | +2.16% |
| 2017 | $140.85 | $143.85 | +2.13% | +21.70% | (19.57%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
